Follow
Mohammad hojjat-farsangi
Mohammad hojjat-farsangi
Karolinska university Hospital Solna
Verified email at ki.se
Title
Cited by
Cited by
Year
Nanoparticles and targeted drug delivery in cancer therapy
B Bahrami, M Hojjat-Farsangi, H Mohammadi, E Anvari, G Ghalamfarsa, ...
Immunology letters 190, 64-83, 2017
5012017
Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies
M Hojjat-Farsangi
International journal of molecular sciences 15 (8), 13768-13801, 2014
2632014
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
A Masjedi, V Hashemi, M Hojjat-Farsangi, G Ghalamfarsa, G Azizi, ...
Biomedicine & Pharmacotherapy 108, 1415-1424, 2018
2612018
Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer
MH Kazemi, S Raoofi Mohseni, M Hojjat‐Farsangi, E Anvari, ...
Journal of Cellular Physiology 233 (3), 2032-2057, 2018
1372018
Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells
AH Daneshmanesh, M Hojjat-Farsangi, AS Khan, M Jeddi-Tehrani, ...
Leukemia 26 (6), 1348-1355, 2012
1322012
CD73 as a potential opportunity for cancer immunotherapy
G Ghalamfarsa, MH Kazemi, S Raoofi Mohseni, A Masjedi, ...
Expert opinion on therapeutic targets 23 (2), 127-142, 2019
1282019
Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy
B Bahrami, M Mohammadnia-Afrouzi, P Bakhshaei, Y Yazdani, ...
Tumor Biology 36, 5727-5742, 2015
1252015
The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia
S Eghbal‐Fard, M Yousefi, H Heydarlou, M Ahmadi, S Taghavi, ...
Journal of Cellular Physiology 234 (4), 5106-5116, 2019
1202019
The receptor tyrosine kinase ROR1–an oncofetal antigen for targeted cancer therapy
M Hojjat-Farsangi, A Moshfegh, AH Daneshmanesh, AS Khan, ...
Seminars in cancer biology 29, 21-31, 2014
1082014
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
AH Daneshmanesh, A Porwit, M Hojjat-Farsangi, M Jeddi-Tehrani, ...
Leukemia & lymphoma 54 (4), 843-850, 2013
972013
Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer
V Karpisheh, A Nikkhoo, M Hojjat-Farsangi, A Namdar, G Azizi, ...
Prostaglandins & other lipid mediators 144, 106338, 2019
942019
Mechanisms of tumor cell resistance to the current targeted-therapy agents
G Khamisipour, F Jadidi-Niaragh, AS Jahromi, K Zandi, M Hojjat-Farsangi
Tumor Biology 37, 10021-10039, 2016
782016
Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells
M Hojjat-Farsangi, F Ghaemimanesh, AH Daneshmanesh, AA Bayat, ...
PloS one 8 (4), e61167, 2013
782013
CDK1 in breast cancer: implications for theranostic potential
S Izadi, A Nikkhoo, M Hojjat-Farsangi, A Namdar, G Azizi, H Mohammadi, ...
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2020
772020
Blockage of immune checkpoint molecules increases T‐cell priming potential of dendritic cell vaccine
H Hassannia, M Ghasemi Chaleshtari, F Atyabi, M Nosouhian, A Masjedi, ...
Immunology 159 (1), 75-87, 2020
702020
Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression
F Jadidi-Niaragh, M Yousefi, A Memarian, M Hojjat-Farsangi, ...
Cancer investigation 31 (2), 121-131, 2013
702013
The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells
M Hojjat-Farsangi, AS Khan, AH Daneshmanesh, A Moshfegh, Å Sandin, ...
PloS one 8 (10), e78339, 2013
692013
Quantum dots as targeted doxorubicin drug delivery nanosystems in human lung cancer cells
M Ruzycka-Ayoush, P Kowalik, A Kowalczyk, P Bujak, AM Nowicka, ...
Cancer Nanotechnology 12, 1-27, 2021
662021
Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway
A Masjedi, H Hassannia, F Atyabi, A Rastegari, M Hojjat-Farsangi, ...
International journal of biological macromolecules 133, 436-445, 2019
652019
Anti‐angiogenic effects of CD73‐specific siRNA‐loaded nanoparticles in breast cancer‐bearing mice
G Ghalamfarsa, A Rastegari, F Atyabi, H Hassannia, M Hojjat‐Farsangi, ...
Journal of cellular physiology 233 (10), 7165-7177, 2018
632018
The system can't perform the operation now. Try again later.
Articles 1–20